| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Departments of Endocrinology (R.M.C., M.A., J.S., H.F.E.-M.) and Molecular Genetics (D.T., J.L.S.M.), Hospital Ramón y Cajal, Madrid 28034, Spain
Address all correspondence and requests for reprints to: Héctor F. Escobar-Morreale, M.D., Ph.D., Department of Endocrinology, Hospital Ramón y Cajal, Carretera de Colmenar Km 9'100, 28034 Madrid, Spain. E-mail: hector.escobar{at}uam.es
Abstract
Abnormalities in adrenal and/or ovarian steroidogenesis are found in most patients with hirsutism. The rate-limiting step in the synthesis of steroids in the ovary and the adrenal is the conversion of cholesterol into pregnenolone by cholesterol side-chain cleavage enzyme (P450scc), encoded by the gene CYP11A, after cholesterol is introduced into the mitochondria by the steroidogenic acute regulatory protein (StAR). DAX-1 is a repressor of StAR gene expression, and steroidogenic factor-1 (SF-1) is a regulator of CYP11A, DAX-1, and StAR gene. Mutations in any of these factors resulting in gain of function, or loss of repression, of StAR or P450scc might contribute to the steroidogenic abnormalities present in hirsute patients.
In the present study we have screened, using heteroduplex analysis, the
genes encoding StAR and SF-1 as well as DAX-1 and CYP11A
for mutations in genomic DNA from 19 women presenting with hirsutism
and increased serum androgen levels. When variants were found, analysis
was extended to a larger group of hyperandrogenic patients and
nonaffected women. Two variants were identified in the SF-1 gene. A
G
C change in exon 6, resulting in an Arg365Pro mutation,
was found in 1 of 45 patients, but not in controls. Also, a
Gly146Ala missense mutation, resulting from a G
C change
in exon 4, was found in 2 of 48 patients and in 2 of 50 nonaffected
individuals. We identified a C
T base pair change at position -33 of
the StAR gene. Three of 48 patients and 3 of 43 controls presented this
variant. No mutations were found in coding regions of the StAR gene.
Analysis of CYP11A-coding regions identified a G
A
change in exon 3, resulting in a Val179Ile missense
mutation. This mutation was found in 1 of 29 patients studied and was
not present in 50 controls. Finally, analysis of DAX-1 showed no
variant in any of the women studied.
In conclusion, mutations in StAR, SF-1, CYP11A, and DAX-1 are seldom found in hirsute patients and do not explain the steroidogenic abnormalities found in these women.
This article has been cited by other articles:
![]() |
I. A. Pikuleva CHOLESTEROL-METABOLIZING CYTOCHROMES P450 Drug Metab. Dispos., April 1, 2006; 34(4): 513 - 520. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. F. Escobar-Morreale, M. Luque-Ramirez, and J. L. San Millan The Molecular-Genetic Basis of Functional Hyperandrogenism and the Polycystic Ovary Syndrome Endocr. Rev., April 1, 2005; 26(2): 251 - 282. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Zheng, Y.-T. Gao, X.-O. Shu, W. Wen, Q. Cai, Q. Dai, and J. R. Smith Population-Based Case-Control Study of CYP11A Gene Polymorphism and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., May 1, 2004; 13(5): 709 - 714. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Peral, J. L. San Millan, R. Castello, P. Moghetti, and H. F. Escobar-Morreale The Methionine 196 Arginine Polymorphism in Exon 6 of the TNF Receptor 2 Gene (TNFRSF1B) Is Associated with the Polycystic Ovary Syndrome and Hyperandrogenism J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3977 - 3983. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |